Skip to main content
Evotec SE logo

Evotec SE — Investor Relations & Filings

Ticker · EVT ISIN · DE0005664809 LEI · 529900F9KI6OYITO9B12 F Professional, scientific and technical activities
Open in API
Filings indexed 1,772 across all filing types
Latest filing 2025-06-03 Remuneration Information
Country DE Germany
Listing F EVT

About Evotec SE

https://www.evotec.com/en

Evotec SE is a life science company focused on drug discovery and development in partnership with pharmaceutical and biotechnology firms. The company operates an integrated research and development value chain, utilizing proprietary technology platforms that incorporate AI-driven innovation and induced pluripotent stem cells (iPSC). Its expertise spans a wide range of therapeutic modalities, from small molecules to biotherapeutics. Through its Just – Evotec Biologics division, the company offers end-to-end solutions for the design, development, and manufacturing of biologic therapies, aiming to enhance their accessibility and affordability. Evotec employs flexible partnering models to accelerate the delivery of new treatments to patients with high efficiency and quality.

Recent filings

Filing Released Lang Actions
Remuneration Report 2024 of Evotec SE
Remuneration Information Classification · 1% confidence The document is titled 'Remuneration report 2024 of Evotec SE'. It provides detailed information on the compensation structure, fixed and variable remuneration components, and fringe benefits for members of the Management Board and Supervisory Board. This content aligns perfectly with the definition of a Remuneration Information report (DEF 14A), which covers executive and director compensation.
2025-06-03 English
Q1 statement / Q1 financial report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'INTERIM STATEMENT 3M 2025' and provides a comprehensive breakdown of financial performance for the first three months of 2025, including consolidated income statements, segment information, and detailed analysis of operations, cash flow, and financial position. It contains substantive financial data and analysis, distinguishing it from a mere announcement or certification. Therefore, it is classified as an Interim/Quarterly Report. Q1 2025
2025-05-13 English
Evotec receives $ 2.5 m grant to generate next generation tuberculosis treatments
Regulatory Filings Classification · 1% confidence The document is a short corporate announcement dated May 7, 2025, detailing that Evotec SE received a $2.5 million grant from the Gates Foundation for tuberculosis treatment research. It contains key highlights, quotes, and boilerplate information about the company and the disease. It is not a full Annual Report (10-K), an Interim Report (IR), or a detailed Investor Presentation (IP). It is a specific announcement of a corporate event/funding, which fits best under a general regulatory announcement or news release category. Since it is not a specific financial filing like 10-K, DIV, or ER, and it is not merely announcing the publication of another report (RPA), the most appropriate general category for this type of material, especially when distributed via a service like EQS News, is Regulatory Filings (RNS), which serves as a broad category for miscellaneous corporate news that doesn't fit the highly specific financial/governance codes.
2025-05-08 English
Evotec SE reports Q1 2025 results: Paving the way for 2025 growth in soft market environment
Earnings Release Classification · 1% confidence The document explicitly states it reports the 'financial results for Q1 2025' and provides key figures like Group revenues (€ 200 m) and Adjusted Group EBITDA (€ 3.1 m) for the first quarter. It also confirms the '2025 Guidance and 2028 Outlook'. This content structure—summarizing recent quarterly performance, providing key metrics, and confirming future guidance—is characteristic of an Earnings Release (ER). Although it mentions that more detailed information is available in the annual report, the document itself is the initial announcement of the period's results, not the comprehensive annual report (10-K) or a general announcement about a report's publication (RPA). Q1 2025
2025-05-06 English
Presentation Q1 2025
Earnings Release Classification · 1% confidence The document explicitly states "Q1 2025 results" and contains detailed financial tables for "Q1 2025" compared to "Q1 2024", including revenue, gross margin, and Adjusted Group EBITDA. It also mentions a conference call date ("Evotec SE, Q1 2025 results call, 06 May 2025") and includes sections for "Financials" and "Questions & Answers". This structure is characteristic of an Earnings Release (ER) or a presentation accompanying an earnings call. Since it provides detailed financial figures and commentary, it is more comprehensive than a simple press release, but it is presented as a results call presentation, which often serves as the primary material for the initial results announcement. Given the options, 'ER' (Earnings Release) is the most appropriate classification for a document detailing period-specific financial results (Q1 2025). It is not a full Annual Report (10-K) or a comprehensive Interim Report (IR) which usually implies a formal filing document, but rather the presentation material for the results announcement. Q1 2025
2025-05-06 English
Evotec SE to announce results for the first quarter 2025 on 6 May 2025
Report Publication Announcement Classification · 1% confidence The document is a corporate news release dated April 29, 2025, announcing that Evotec SE will release its financial results for the first quarter of 2025 on May 6, 2025. It provides details for the subsequent conference call and webcast. Since this document is an announcement *about* the upcoming release of quarterly results, rather than the results themselves (which would be an Interim Report (IR) or Earnings Release (ER)), it fits the definition of a Report Publication Announcement (RPA). It is not the full report, but the notice of its publication/discussion event.
2025-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.